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Between November 2012 and July 2014, in accordance with nationallaw 648/96, brentuximab vedotin was available in Italy for patientswith relapsed systemic anaplastic large cell lymphoma outside a
clinical trial context. A large Italian observational retrospective study was
conducted on the use of brentuximab vedotin in everyday clinical prac-
tice to check whether clinical trial results are confirmed in a real-life con-
text. The primary endpoint of this study was best response; secondary
endpoints were the overall response rate at the end of the treatment,
duration of response, survival and safety profile. A total of 40 heavily
pretreated patients were enrolled. Best response was observed after a
median of four cycles in 77.5%: globally, 47.5% patients obtained a com-
plete response, 64.2% in the elderly subset. The overall response rate
was 62.5%. At the latest follow up, 15/18 patients are still in complete
remission (3 with consolidation). The progression-free survival rate at 24
months was 39.1% and the disease-free survival rate at the same time
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ABSTRACT
Introduction
Approximately 40% to 65% of patients with systemic
anaplastic large-cell lymphoma (ALCL) develop recurrent
disease after front-line therapy.1 Historically, at relapse the
disease is resistant to conventional multiagent chemothera-
py regimens and there is no established standard of care.
High-dose therapy and autologous stem cell transplantation
(SCT) may result in long-term remission in 30% to 40% of
patients, but the benefit is limited to patients with
chemotherapy-sensitive disease.2-6
Given that most patients with relapsed or refractory (R/R)
systemic ALCL are scheduled to undergo a highly toxic
high-dose chemotherapy regimen, any strategy aimed at
achieving minimal residual disease, specifically a positron
emission tomography-negative status before autologous
SCT, without severe toxicity would represent a major
advance in the overall management of these patients.
Furthermore, despite the role of autologous SCT, the out-
comes remain poor in patients with primary chemorefrac-
tory disease, in whom long-term survival rarely exceeds 15-
17%.1 In fact, disease recurrence still remains the principal
cause of failure of autologous SCT, and early disease pro-
gression after transplantation, i.e. within 6 months of high-
dose conditioning, emerges as the most important predictor
of an unfavorable outcome. No standard treatment options
exist for patients whose disease relapses after autologous
SCT or for patients not eligible for autologous SCT. In fact,
while allogeneic SCT may induce long-term progression-
free survival in a fraction of patients, only a few are candi-
dates for this procedure, mainly because of unsatisfactory
pre-transplant cytoreduction and the substantial risk of
morbidity due to the heavy load of previous therapies. In
this light, optimization of the outcomes obtained with
high-dose regimens and autologous SCT still remains a
strategic priority, in order to offer the best chance of cure for
the largest fraction of patients with R/R disease.
Brentuximab vedotin (BV) is an antibody-drug conjugate
targeting CD30 which may be an excellent candidate
among the newly developed agents for the treatment of
R/R systemic ALCL.7 In fact, systemic ALCL is character-
ized by the expression of CD30. In the initial phase 1 study
of BV in patients with CD30+ lymphoid diseases, the two
patients with systemic ALCL both achieved a complete
response.7 The favorable activity of this agent in R/R sys-
temic ALCL was clearly documented by Pro et al. in a phase
2 study involving 58 patients: 86% obtained a response,
which was a complete response in 57% of cases.8 The
median progression-free survival of these patients was 13.3
months, and the median overall survival was not reached
(estimated 64% at 4 years). The same relevant proportion
of complete responses in this subset of patients also
emerged from the data collected by Zinzani et al. regarding
the BV Named Patient Program experiences across
Europe.9,11,15-17
A high response rate is important not only in pretreated
patients with a poor prognosis, but also in first-line R/R
patients because a complete response obtained before
transplantation is one of the stronger predictors of long-
term survival.10 BV could represent an optimal therapeutic
option as a bridge to either autologous or allogeneic SCT in
patients achieving a suboptimal response after salvage treat-
ment.11,12 Recent updates on the pivotal study have shown
that BV can induce long-lasting complete responses in pre-
treated cases of systemic ALCL even without additional
consolidation therapies, suggesting that BV may be curative
for some patients.13,14 The pooled overall response rate and
complete response rate reported for patients with R/R sys-
temic ALCL (globally 46) in the Named Patient Program
cohorts were both 69.5%.9,11,15-17 
After accelerated approval by the US Food and Drug
Administration, eligible patients in Italy were granted early
access to BV through a Named Patient Program. After clo-
sure of this program in 2012, BV was available in Italy for
patients with R/R systemic ALCL, based on a local disposi-
tion of the Italian Drug Agency (AIFA) issued in accordance
with a national law (Law 648/96: “medicinal products that
are provided free of charge on the national health service”):
a boundary zone in the passage from clinical trials to mar-
keting and free use phases in which patients can be treated
in any case. 
On the basis of our previous exploratory study,18 a large
observational retrospective study was conducted on the use
of BV in R/R systemic ALCL patients in everyday clinical
practice in Italy to check whether clinical trial results are
confirmed in a real-life context.
Methods
An observational retrospective study was conducted among
patients with systemic ALCL treated from November 2012 to July
2014 with BV in 38 Italian centers outside of clinical trials, in accor-
dance with national law n. 648/96.19 The study was approved by
the institutional board of the Policlinico S.Orsola-Malpighi
Hospital in Bologna, the coordinating center of the study, and by
all the ethical committees involved and registered in the Italian
Registry of Observational Studies. All participants gave written
informed consent in accordance with the Declaration of Helsinki.
A shared database was used after the approval of all the co-inves-
tigators and variables were strictly defined to avoid bias in report-
ing data.19 We obtained special permission (for scientific purposes)
from our ethical committee to collect data regarding patients who
could not consent because they had died or been lost to follow up. 
BV was administered as a 30-min infusion at the dose of 1.8
mg/kg of body weight every 3 weeks for a maximum of 16 cycles.
A dose reduction to 1.2 mg/kg was recommended in the case of
grade 3 toxicity and the treatment had to be interrupted in the case
of grade 4 toxicity. 
The primary endpoint of the study was the best response
A. Broccoli et al.
1932 haematologica | 2017; 102(11)
was 54% (median not reached). All the long-term responders were aged <30 years at first infusion. The
treatment was well tolerated even in this real-life context and no deaths were linked to drug toxicity.
Brentuximab vedotin induces clinical responses quite rapidly, i.e. within the first four cycles of treatment
in most responders, thus enabling timely use of transplantation. For patients ineligible for transplant or
for those in whom a transplant procedure failed, brentuximab vedotin may represent a feasible effective
therapeutic option in everyday clinical practice.
achieved during BV therapy; secondary endpoints were the overall
response rate at the end of the treatment, duration of response,
overall survival, progression-free survival, disease-free survival,
and the drug’s safety and tolerability. Duration of therapy was
defined as the number of cycles of treatment administered.
Effectiveness was also evaluated through the occurrence of long-
term responders, defined as patients who had a response (com-
plete or partial) lasting ≥12 months. Response was assessed by
positron emission tomography or computed tomography scanning
after cycles 4, 8, 12 and at drug discontinuation by each investiga-
tor using the International Working Group revised response crite-
ria for malignant lymphoma.20 Safety and tolerability were evalu-
ated by recording the incidence, severity, and type of any adverse
events according to the National Cancer Institute Common
Terminology Criteria for Adverse Events version 4.0. 
Overall survival was defined as the time from initiation of ther-
apy to death from any cause and was censored at the date of the
last available follow up. Progression-free survival was measured
from initiation of therapy to progression, relapse, or death from
any cause and was censored at the date of the last available follow
up. Disease-free survival was calculated for patients who achieved
a complete response from the first documentation of response to
the date of relapse or death due to lymphoma or acute toxicity of
treatment. Duration of response was calculated from the first
objective tumor response (complete or partial) to first documenta-
tion of progression or death.20 Patients who were lost to follow up
(n=2) were censored at the date of their last available information.
Demographics and patients’ characteristics as well as adverse
events were summarized by descriptive statistics. Survival func-
tions were estimated using the Kaplan-Meier method and com-
pared using the log-rank test. Statistical analyses were performed
with Stata 11 (StataCorp LP, TX, USA) and P values <0.05 were
considered statistically significant.
Results
Of the estimated 40 patients who received BV under Law
648/96, all participated in this observational study. All had
histologically confirmed CD30+ disease. Their median age
at the time of being treated with BV was 47 years (range,
17-80 years) with 14 (35.0%) being considered elderly (age
>60 years). There were 28 males and 12 females. Eleven
(27.5%) had systemic symptoms at baseline (Table 1).
The median number of prior lymphoma-related systemic
regimens was two (range, 2-10) and included high-dose
chemotherapy and autologous SCT (in 13, 32.5% of the
patients). Eight patients (20%) had received prior radiation
therapy. Eighteen were negative for anaplastic lymphoma
kinase (ALK-negative), while 22 were positive (ALK-posi-
tive). Each patient’s status after both frontline therapy and
most recent therapy was recorded:  24 (60%) patients had
disease that was refractory to frontline therapy and 25
patients (62.5%) had disease that was refractory to the last
therapy before BV. 
Response to treatment 
Best response was observed after a median of four cycles
of treatment in 31 (77.5%) patients: 19 (47.5%) obtained a
complete response and 12 (30%) achieved a partial
response. The overall response rate at the end of the treat-
ment was 62.5% (25 patients), represented by 18 (45%)
complete responses and seven (17.5%) partial responses; of
the remaining patients, one had stable disease, and 14
patients showed disease progression.
The best response rate was higher in the elderly subset
(>60 years): nine (64.3%) complete responses and three
(21.4%) partial responses for an overall response rate of
85.7%. Four patients who were in complete remission at
first restaging relapsed during further BV courses; two
patients who had a partial response at first restaging con-
verted to complete response status after the four subse-
quent infusions. 
None of the patients who had stable or progressive dis-
ease at first restaging had an improvement in their status at
the end of therapy. The median number of treatment cycles
administered was eight (range, 1-16).
With a median follow up of 18 months, the global overall
survival rate was 56.9% at 24 months (Figure 1) and the
median had not been reached. The progression-free sur-
vival rate at 24 months was 39.1%, with the median
achieved at 12.5 months (Figure 2). The disease-free sur-
vival rate at 24 months was 54% (Figure 3). Of the 19
patients who had a complete response, 4 (21%) relapsed
and 15 were in continuous complete response at the last fol-
low up with a median duration of response of 12 months
(range, 9-24 months). After controlling for confounding
variables, no differences were observed between ALK-neg-
ative and ALK-positive patients for any times to endpoints.
Among the patients who achieved complete responses,
three were given consolidation with transplantation (1
autologous and 2 allogeneic SCT). Currently, 15 patients are
Brentuximab vedotin in ALCL:  real-life experience
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Figure 1. Overall survival. Figure 2. Progression free-survival.
still in complete response, including the three who under-
went a consolidation procedure. Of the nine elderly
patients, six (66.7%) are still in continuous complete
response without any consolidation procedure after a medi-
an of 14 months. 
There were five long-term responders, all of whom were
still in continuous complete response at the last available
follow up. Of note, they were all aged <35 years at the time
of starting BV therapy and only one of them had a subse-
quent consolidative transplant. 
At the latest follow-up, 27 (67.5%) patients were alive
and 13 had died. Of the 13 deaths, 11 were due to lym-
phoma and two were caused by complications after allo-
geneic SCT (1 case of respiratory failure related to graft-ver-
sus-host disease and 1 case of pneumonia).
Safety
All patients who received at least one BV infusion were
included in the safety analysis. In general, the treatment
was well tolerated and the toxicity profile was very similar
to that previously published. Twelve patients had at least
one toxicity. All hematologic toxicities were grade 1-2,
except one case of grade 3 neutropenia. The extra-hemato-
logic side effects were mostly represented by peripheral
sensory neurological toxicity (15/20), including three cases
of grade 3. The other adverse events were nausea grade 1-
2 (2 patients), erythema grade 2 (2 patients), and hyposthe-
nia grade 2 (1 patient). Neurological toxicity always
reversed completely after the end of treatment. No long-
term toxicity related to BV was observed during the follow-
up period, even in patients later subjected to consolidation
with transplantation.
Discussion
This retrospective, large, multicenter Italian study on 40
patients with R/R systemic ALCL treated with BV outside
a clinical trial represents the largest ever reported in a real-
world context. Our results are in accordance with the piv-
otal phase II study and its updates and the other national
experience studies with an overall response rate of 77.5%
and a complete response rate of 47.5% in terms of best
response.8,9,11,14-18
In addition, we gained some interesting insights into the
role of BV in everyday clinical practice. First, both the best
response rate and overall response rate were higher among
elderly patients: 85.7% versus 77.5% and 64.3% versus
62.5%, respectively.
It was confirmed that having a complete response after
four cycles of treatment is very important for classifying a
patient as a real good responder; however, the best number
of cycles to give with a view to evaluating potential consol-
idation with transplantation (in most cases with allogeneic
transplantation) or continuation with BV until cycle 16
remains an open issue, mainly because in the case of a com-
plete response the choice between the two options is at the
physician’s discretion. According to the recent update from
Pro et al. on the pivotal phase II study, the 5-year progres-
sion-free survival rate was 68% in patients who achieved a
complete response and underwent allogeneic SCT versus
47% in patients who continued BV treatment even though
they had obtained a complete response after the first four
cycles of treatment.8,14 In this update the authors reported
that 27.6% of the whole study population achieved long-
term remission, lasting for more than 5 years, in response to
single agent BV without any additional anticancer therapy,
other than transplantation. In our study the estimated dis-
ease-free survival rate at 2 years was 54% and 15 patients
(37.5%) were in continuous complete response with a
median duration of response of 12 months (range, 9-24
months). As only three of those 15 patients had had trans-
plant consolidation, a comparison between these patients
and those who did not undergo a SCT procedure was not
possible. Thus, the duration of response and disease-free
survival in the real-life experience, confirming the findings
of the pivotal study, indicate that a substantial subset of
patients with R/R systemic ALCL who have a complete
response with single agent BV obtain long-term disease
control and may potentially be cured. One important ques-
tion remains unanswered: which of the patients in com-
plete response may benefit from transplant consolidation?
In our series there were five long-term responders, all of
whom were still in continuous complete response at the lat-
est follow-up, but of whom only one had undergone a con-
solidative allogeneic SCT procedure. Updates from the piv-
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Table 1. Patients’ demographics and characteristics at baseline.
Total population, N 40
ALK-positive 22
ALK-negative 18
Median age, years (range) 51.4 (22.6-80.7)
Median time from diagnosis-BV, years (range) 2 (1-16)
Male, n (%) 28 (70.0)
Stage, n (%)
I/II 9 (22.5)
III 5 (12.5)
IV 26 (65.0)
Systemic symptoms, n (%) 11 (27.5)
Refractory to most recent therapy, n (%) 24 (60.0)
Refractory to first-line therapy, n (%) 25 (62.5)
Median number of previous therapies (range) 2 (2-10)
Prior autologous stem cell transplant, n (%) 13 (32.5)
Prior radiotherapy, n (%) 8 (20)
ALK: anaplastic lymphoma kinase; BV: brentuximab vedotin.
Figure 3. Disease-free survival.
otal study and our data could indicate that long-term dis-
ease control can be obtained even without transplant con-
solidation, with a real chance of curing a subset of patients
with R/R systemic ALCL with BV alone.14 Physicians are
still divided on whether or not to offer a consolidative
transplant to patients in complete response because solid
clinical trial data are lacking on this issue. A large, well-
designed randomized control study is needed, but ALCL is
so rare that we are unlikely ever to have a definitive answer.
Differences in survival outcomes between ALK-positive
and ALK-negative patients have often been reported: no
statistically significant difference was observed between
the two subgroups in our sample.21
Our study indicated that for patients who had stable or
progressive disease after four cycles of BV the potential con-
version rate to partial or complete response with further
cycles is close to zero. The final message is that when
patients have stable or progressive disease at first restaging,
they should be changed rapidly to another treatment. On
the other hand, for patients who achieve a partial response
by the first restaging, it could be important to continue the
treatment: in our series 2/12 (16.7%) patients showed a
conversion from a partial to a complete response. 
In conclusion, the results of this large retrospective
study on 40 cases of R/R systemic ALCL in daily practice
support the efficacy of single-agent BV, which appears to
be a treatment with manageable toxicity without evi-
dence of cumulative toxic effects with previous regimens.
We acknowledge that this kind of report has a potential
bias given the lack of a predictable and calculated sample
size and the risk of underreporting toxicity. However,
ALCL is a very rare disease, accounting for approximately
2% to 3% of all lymphoid neoplasms. The phase II study
that led to Food and Drug Administration-accelerated
approval of BV enrolled 58 patients globally, thus 40 ALCL
patients from a single nation is a substantial sample relat-
ed to this pathology. Nevertheless, we could not analyze
prognostic features due to the small sample and we have
reported the raw observed data. Compared with random-
ized controlled trials, observational studies may better
identify clinically important adverse events for several rea-
sons. These include longer follow-up times, the inclusion
of patients with concomitant illnesses who may be more
likely to experience drug interactions or other side effects
and the probability of detecting infrequent or rare compli-
cations. With regards to the retrospective nature of this
specific study, AIFA demands strict monitoring of drugs
prescribed under law 648/96 and physicians must report
any adverse event occurring during treatment: thus, all the
safety data were already in the patients’ chart at the time
our retrospective study started.
Our report confirms the activity of BV in elderly patients,
the duration of the clinical response independently of trans-
plant consolidation, and the relevance to the final response
of achieving a complete response after four cycles of treat-
ment. BV is the first drug which has led to a drastic change
in the management of ALCL, with an overall response rate
of 80%. The next research efforts could be aimed at devel-
oping combination regimens with BV to reach a 100% rate
of responses in patients with R/R ALCL
Brentuximab vedotin in ALCL:  real-life experience
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